Globus Medical Inc. Class A Common Stock vs Tapestry, Inc. — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.85 (market cap $10.25B), while Tapestry, Inc. trades at $116.23 (market cap $22.83B). The key difference: Tapestry, Inc. is far larger — about 2.2× Globus Medical Inc. Class A Common Stock's market cap, and Tapestry, Inc. pays a 1.61% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Tapestry, Inc. for 70 Days on average.
| GMED | TPR | |
|---|---|---|
Market Cap | $10.25B | $22.83B |
Volume | 1,059,528 | 1,359,849 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $164.78 |
52-Week Low | $58.33 | $98.81 |
Typical Hold Time | 0 Days | 70 Days |
Enterprise Value | $9.76B | $25.63B |
Dividend Yield | — | 1.61% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
TPR trades at $115.23, down 1.7% today, with neutral technical signals and strong analyst support. The stock shows robust profitability with 77.8% gross margins and has beaten earnings estimates for three consecutive quarters. Recent developments include expansion into Google's AI shopping ecosystem, positioning the company for digital growth. Valuation metrics appear reasonable with a P/E of 15.8x, though the high P/B ratio of 32.9x warrants attention given the premium to book value.
The investment case balances strong brand momentum and international growth against execution risks and tariff pressures. With 73% analyst buy ratings and a $174.64 consensus target suggesting 52% upside, the stock offers growth potential. However, investors face risks from Kate Spade's performance challenges and volatile cash flow patterns that require careful monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →